Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria

Yuki Nemoto(Tokyo Women's Medical University Adachi Medical Center), Toshio Takagi(Tokyo Women's Medical University), Hidekazu Tachibana, Hirohito Kobayashi(Ebina General Hospital), Kazuhiko Yoshida(Tokyo Women's Medical University Hospital), Tsunenori Kondo(Tokyo Women's Medical University Adachi Medical Center), Hironori Fukuda(Tokyo Women's Medical University), Hiroki Ishihara(Tokyo Women's Medical University), Yasunobu Hashimoto, Kazunari Tanabe(Shonan Kamakura General Hospital), Hiroaki Shimmura(Jyoban Hospital of Tokiwa Foundation), Junpei Iizuka(Tokyo Women's Medical University), Kazutaka Nakamura(Tokyo Women's Medical University Hospital)
Targeted Oncology
July 1, 2022
Cited by 5


Related Papers